Sunshine Biopharma (NASDAQ:SBFM) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Sunshine Biopharma (NASDAQ:SBFM) to a hold rating in a report published on Saturday.

Several other equities research analysts have also recently weighed in on SBFM. Weiss Ratings cut Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday. Zacks Research upgraded Sunshine Biopharma to a “hold” rating in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sunshine Biopharma currently has an average rating of “Hold” and an average target price of $70.00.

Sunshine Biopharma Stock Down 4.2%

SBFM opened at $1.15 on Friday. Sunshine Biopharma has a twelve month low of $1.10 and a twelve month high of $24.30. The company has a 50-day simple moving average of $1.82 and a 200 day simple moving average of $6.90. The stock has a market capitalization of $576,150.00, a price-to-earnings ratio of -0.11 and a beta of 1.16.

Sunshine Biopharma (NASDAQ:SBFM) last released its earnings results on Thursday, August 13th. The company reported ($1.15) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.05. The firm had revenue of $9.26 million for the quarter, compared to analyst estimates of $8.70 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 27.69%. Sell-side analysts anticipate that Sunshine Biopharma will post -6.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Sunshine Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in SBFM. Citadel Advisors LLC increased its holdings in shares of Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after buying an additional 14,656 shares in the last quarter. Two Sigma Investments LP bought a new stake in Sunshine Biopharma during the 3rd quarter worth $32,000. Finally, Virtu Financial LLC acquired a new position in Sunshine Biopharma in the 4th quarter worth about $29,000. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.